Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.36 Million USD | 96.91% |
| 2022 | -41.02 Million USD | -17067.97% |
| 2021 | -238.99 Thousand USD | -10.2% |
| 2020 | -216.87 Thousand USD | 67.53% |
| 2019 | -667.98 Thousand USD | -53.17% |
| 2018 | -436.11 Thousand USD | -1116.51% |
| 2017 | -35.85 Thousand USD | -2.41% |
| 2016 | -35 Thousand USD | -141.05% |
| 2015 | -14.52 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | -1.26 Million USD | 96.91% |
| 2023 Q2 | -203.61 Thousand USD | 72.35% |
| 2023 Q3 | -203.61 Thousand USD | 0.0% |
| 2023 Q4 | 201.33 Thousand USD | 198.88% |
| 2023 Q1 | -736.28 Thousand USD | -17.09% |
| 2022 Q1 | -361.07 Thousand USD | -360.3% |
| 2022 FY | -41.02 Million USD | -17067.97% |
| 2022 Q4 | -628.82 Thousand USD | 60.58% |
| 2022 Q3 | -1.59 Million USD | 10.49% |
| 2022 Q2 | -1.78 Million USD | -393.63% |
| 2021 FY | -238.99 Thousand USD | -10.2% |
| 2021 Q3 | -47.09 Thousand USD | 16.31% |
| 2021 Q2 | -56.27 Thousand USD | 1.58% |
| 2021 Q1 | -57.17 Thousand USD | -138.64% |
| 2021 Q4 | -78.44 Thousand USD | -66.55% |
| 2020 Q3 | -199.57 Thousand USD | -84.5% |
| 2020 Q2 | -108.17 Thousand USD | -89.43% |
| 2020 Q4 | 147.96 Thousand USD | 174.14% |
| 2020 Q1 | -57.1 Thousand USD | 68.07% |
| 2020 FY | -216.87 Thousand USD | 67.53% |
| 2019 Q3 | -143.25 Thousand USD | 7.15% |
| 2019 Q2 | -154.28 Thousand USD | 19.47% |
| 2019 Q1 | -191.59 Thousand USD | 29.78% |
| 2019 FY | -667.98 Thousand USD | -53.17% |
| 2019 Q4 | -178.84 Thousand USD | -24.84% |
| 2018 Q4 | -272.83 Thousand USD | -1347.63% |
| 2018 Q2 | -121.77 Thousand USD | -437.35% |
| 2018 Q1 | -22.66 Thousand USD | -49.43% |
| 2018 FY | -436.11 Thousand USD | -1116.51% |
| 2018 Q3 | -18.84 Thousand USD | 84.52% |
| 2017 Q3 | -3975.00 USD | 15.44% |
| 2017 Q4 | -15.16 Thousand USD | -281.53% |
| 2017 FY | -35.85 Thousand USD | -2.41% |
| 2017 Q1 | -12 Thousand USD | -71.54% |
| 2017 Q2 | -4701.00 USD | 60.85% |
| 2016 Q1 | -7844.00 USD | -169.37% |
| 2016 Q4 | -7000.00 USD | 53.33% |
| 2016 Q3 | -15 Thousand USD | -190.47% |
| 2016 Q2 | -5164.00 USD | 34.17% |
| 2016 FY | -35 Thousand USD | -141.05% |
| 2015 FY | -14.52 Thousand USD | 0.0% |
| 2015 Q2 | -2034.00 USD | 0.0% |
| 2015 Q3 | -3820.00 USD | -87.81% |
| 2015 Q4 | -2912.00 USD | 23.77% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -177.561% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 85.634% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 95.441% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 97.963% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 91.369% |
| Better Therapeutics, Inc. | -38.26 Million USD | 96.426% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 96.75% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 88.577% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 95.96% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 96.027% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 98.739% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | 32.116% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 95.979% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 97.088% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 93.142% |
| Molecular Templates, Inc. | -10.46 Million USD | 86.935% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 90.268% |
| NexImmune, Inc. | -29.19 Million USD | 95.316% |
| Orgenesis Inc. | -53.63 Million USD | 97.451% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 97.334% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -1652.677% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 91.531% |
| Scopus BioPharma Inc. | -11.71 Million USD | 88.328% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 99.729% |
| Statera Biopharma, Inc. | -98.34 Million USD | 98.61% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 80.177% |
| Trevena, Inc. | -35.28 Million USD | 96.125% |
| Vaxxinity, Inc. | -58.28 Million USD | 97.654% |
| Vaccinex, Inc. | -22.88 Million USD | 94.025% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -30.603% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 97.303% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 81.173% |